BioNexus Gene Lab Corp. Equity Securities, FV-NI, Realized Loss
BioNexus Gene Lab Corp. (BGLC) reported Equity Securities, FV-NI, Realized Loss of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedLoss · last filed 2026-08-14
- BioNexus Gene Lab Corp. equity securities, fv-ni, realized loss for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- BioNexus Gene Lab Corp. equity securities, fv-ni, realized loss for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- BioNexus Gene Lab Corp. equity securities, fv-ni, realized loss for the quarter ending 2025-12-31 was -$25.53K.
- BioNexus Gene Lab Corp. equity securities, fv-ni, realized loss for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- BioNexus Gene Lab Corp. equity securities, fv-ni, realized loss for fiscal 2025 was $93.97K.
- BioNexus Gene Lab Corp. equity securities, fv-ni, realized loss for fiscal 2024 was $0.00.
| Period end | Equity Securities, FV-NI, Realized Loss 3 month | Equity Securities, FV-NI, Realized Loss 6 month | Equity Securities, FV-NI, Realized Loss 6 month as first filed | Equity Securities, FV-NI, Realized Loss 9 month | Equity Securities, FV-NI, Realized Loss 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | -$25.53K derived: sum of 3 quarters · filed 2026-08-14 | -$25.53K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | -$25.53K derived: sum of 2 quarters · filed 2026-05-15 | -$25.53K derived: sum of 3 quarters · filed 2026-05-15 | $25.47K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-12-31 | -$25.53K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | -$25.53K derived: sum of 2 quarters · filed 2026-04-14 | $25.47K derived: sum of 3 quarters · filed 2026-04-14 | $93.97K 10-K · filed 2026-04-14 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | $51.00K derived: sum of 2 quarters · filed 2025-11-14 | $119.50K 10-Q · filed 2025-11-14 | -$59.93K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-06-30 | $51.00K 10-Q · filed 2025-08-18 | $91.24K 10-Q · filed 2026-08-14 | $119.50K 10-Q · filed 2025-08-18 | -$59.93K derived: sum of 3 quarters · filed 2026-05-15 | $19.07K derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-03-31 | $68.50K 10-Q · filed 2026-05-15 | -$110.94K derived: sum of 2 quarters · filed 2026-05-15 | -$31.94K derived: sum of 3 quarters · filed 2026-05-15 | $24.20K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | -$179.43K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | -$100.43K derived: sum of 2 quarters · filed 2026-04-14 | -$44.30K derived: sum of 3 quarters · filed 2026-04-14 | $0.00 10-K · filed 2026-04-14 | |
| 2024-09-30 | $79.00K 10-Q · filed 2025-11-14 | $135.14K derived: sum of 2 quarters · filed 2025-11-14 | $179.43K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $56.14K 10-Q · filed 2025-08-18 | $100.43K 10-Q · filed 2025-08-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |